1	British	british	JJ	_	2	amod	_
2	pharma	pharma	NN	p2=FW	6	npadvmod	6:AM-TMP
3	major	major	JJ	p2=NN	4	amod	_
4	AstraZeneca	astrazeneca	NNP	_	6	nsubj	6:A0=PAG;24:A0=PAG
5	today	today	NN	_	6	npadvmod	6:AM-TMP
6	rejected	reject	VBD	pb=reject.01	0	root	_
7	a	a	DT	p2=RB	11	det	_
8	higher	high	JJR	p2=RBR	11	amod	_
9	"	"	``	_	11	punct	_
10	final	final	JJ	_	11	amod	_
11	proposal	proposal	NN	_	6	dobj	6:A1=PPT
12	"	"	''	_	11	punct	_
13	of	of	IN	_	11	prep	_
14	$	$	$	_	16	quantmod	_
15	117	0	CD	_	16	number	_
16	billion	#crd#	CD	_	17	nn	_
17	takeover	takeover	NN	_	13	pobj	_
18	by	by	IN	_	11	prep	_
19	US	us	NNP	_	20	nn	_
20	firm	firm	NN	p2=JJ	22	nn	_
21	Pfizer	pfizer	NNP	_	22	nn	_
22	Inc	inc	NNP	_	18	pobj	_
23	,	,	,	_	6	punct	_
24	stating	state	VBG	pb=state.01	6	advcl	_
25	that	that	IN	_	28	complm	_
26	it	it	PRP	_	28	nsubj	28:A0=PAG
27	"	"	``	p2=''	28	punct	_
28	undervalues	undervalue	VBZ	pb=undervalue.01	24	ccomp	24:A1=PPT
29	the	the	DT	_	30	det	_
30	company	company	NN	_	28	dobj	28:A1=PPT
31	"	"	''	_	28	punct	_
32	.	.	.	_	6	punct	_

1	Pfizer	pfizer	NNP	_	2	nn	_
2	Inc	inc	NNP	_	20	nsubj	20:A0
3	,	,	,	_	2	punct	_
4	the	the	DT	_	9	det	_
5	New	new	NNP	_	6	nn	_
6	York	york	NNP	_	8	hmod	_
7	-	-	HYPH	_	8	hyph	_
8	based	base	VBN	_	9	amod	_
9	maker	maker	NN	_	2	appos	_
10	of	of	IN	_	9	prep	_
11	blockbuster	blockbuster	NN	_	12	nn	_
12	drugs	drug	NNS	_	10	pobj	_
13	such	such	JJ	_	14	amod	_
14	as	as	IN	_	12	prep	_
15	Lipitor	lipitor	NNP	p2=NN	14	pobj	_
16	and	and	CC	_	15	cc	_
17	Viagra	viagra	NNP	_	15	conj	_
18	,	,	,	_	20	punct	_
19	had	have	VBD	_	20	aux	_
20	made	make	VBN	pb=make.LV	0	root	_
21	a	a	DT	_	23	det	_
22	final	final	JJ	_	23	amod	_
23	offer	offer	NN	_	20	dobj	35:A1=PPT;20:AM-PRR
24	of	of	IN	_	23	prep	_
25	55	0	CD	_	26	num	_
26	pounds	pound	NNS	_	24	pobj	_
27	a	a	DT	_	28	det	_
28	share	share	NN	_	26	npadvmod	_
29	to	to	TO	p2=IN	30	aux	_
30	Astrazeneca	astrazeneca	VB	p2=NNP|pb=astrazeneca.01	23	infmod	_
31	on	on	IN	p2=RP	30	prep	30:AM-TMP
32	Friday	friday	NNP	_	31	pobj	_
33	,	,	,	_	23	punct	_
34	which	which	WDT	_	35	nsubj	35:R-A1
35	was	be	VBD	pb=be.01	23	rcmod	_
36	15	0	CD	_	38	num	_
37	per	per	NN	p2=IN	38	nn	_
38	cent	cent	NN	_	39	npadvmod	_
39	higher	high	JJR	p2=RBR	35	acomp	35:A2=PRD
40	than	than	IN	_	39	prep	_
41	its	its	PRP$	_	43	poss	_
42	last	last	JJ	_	43	amod	_
43	bid	bid	NN	_	40	pobj	_
44	,	,	,	_	23	punct	_
45	made	make	VBN	p2=VBD|pb=make.05	23	partmod	_
46	on	on	IN	_	45	prep	45:AM-TMP
47	May	may	NNP	_	46	pobj	_
48	2	0	CD	_	47	num	_
49	.	.	.	_	20	punct	_

1	Reacting	react	VBG	p2=NN|pb=react.01	8	advcl	8:AM-ADV
2	to	to	IN	_	1	prep	1:A1=PAG
3	the	the	DT	_	5	det	_
4	final	final	JJ	_	5	amod	_
5	proposal	proposal	NN	_	2	pobj	_
6	,	,	,	_	8	punct	_
7	AstraZeneca	astrazeneca	NNP	_	8	nsubj	1:A0=PPT;8:A0
8	said	say	VBD	pb=say.01	0	root	_
9	it	it	PRP	_	10	nsubj	10:A0=PAG;21:A1=PPT
10	undervalued	undervalue	VBD	pb=undervalue.01	8	ccomp	8:A1=PPT
11	the	the	DT	_	12	det	_
12	company	company	NN	_	10	dobj	10:A1=PPT
13	and	and	CC	_	12	cc	_
14	"	"	``	p2=''	17	punct	_
15	its	its	PRP$	_	17	poss	_
16	attractive	attractive	JJ	_	17	amod	_
17	prospects	prospect	NNS	_	12	conj	_
18	and	and	CC	_	10	cc	_
19	has	have	VBZ	_	21	aux	_
20	been	be	VBN	_	21	auxpass	_
21	rejected	reject	VBN	pb=reject.01	10	conj	_
22	by	by	IN	_	21	agent	21:A0=PAG
23	the	the	DT	_	24	det	_
24	board	board	NN	_	22	pobj	_
25	of	of	IN	_	24	prep	_
26	AstraZeneca	astrazeneca	NNP	_	25	pobj	_
27	"	"	''	_	21	punct	_
28	.	.	.	_	8	punct	_

1	"	"	``	_	52	punct	_
2	We	we	PRP	_	4	nsubj	4:A0=PAG
3	have	have	VBP	_	4	aux	_
4	rejected	reject	VBN	pb=reject.01	52	ccomp	52:A1=PPT
5	Pfizer	pfizer	NNP	_	8	poss	_
6	's	's	POS	_	5	possessive	_
7	final	final	JJ	_	8	amod	_
8	proposal	proposal	NN	_	4	dobj	4:A1=PPT
9	because	because	IN	_	11	mark	_
10	it	it	PRP	_	11	nsubj	15:A0=PAG;11:A1=PPT
11	is	be	VBZ	pb=be.01	4	advcl	4:AM-CAU
12	inadequate	inadequate	JJ	_	11	acomp	11:A2=PRD
13	and	and	CC	_	11	cc	_
14	would	would	MD	_	15	aux	15:AM-MOD
15	present	present	VB	p2=JJ|pb=present.01	11	conj	_
16	significant	significant	JJ	_	17	amod	_
17	risks	risk	NNS	_	15	dobj	15:A1=PPT
18	for	for	IN	_	17	prep	_
19	shareholders	shareholder	NNS	_	18	pobj	_
20	,	,	,	_	15	punct	_
21	while	while	IN	_	23	mark	_
22	also	also	RB	_	23	advmod	_
23	having	have	VBG	pb=have.03	15	advcl	_
24	serious	serious	JJ	_	25	amod	_
25	consequences	consequence	NNS	_	23	dobj	23:A1=PPT
26	for	for	IN	_	25	prep	_
27	the	the	DT	_	28	det	_
28	company	company	NN	_	26	pobj	_
29	,	,	,	_	28	punct	_
30	our	our	PRP$	_	31	poss	_
31	employees	employee	NNS	_	28	conj	_
32	and	and	CC	_	31	cc	_
33	the	the	DT	_	37	det	_
34	life	life	NN	_	36	hmod	_
35	-	-	HYPH	_	36	hyph	_
36	sciences	science	NNS	_	37	nn	_
37	sector	sector	NN	_	31	conj	_
38	in	in	IN	_	37	prep	_
39	the	the	DT	_	40	det	_
40	UK	uk	NNP	_	38	pobj	_
41	,	,	,	_	40	punct	_
42	Sweden	sweden	NNP	_	40	conj	_
43	and	and	CC	_	42	cc	_
44	the	the	DT	_	45	det	_
45	US	us	NNP	_	42	conj	_
46	,	,	,	_	52	punct	_
47	"	"	''	p2=``	52	punct	_
48	AstraZeneca	astrazeneca	NNP	p2=VBZ	49	nn	_
49	Chairman	chairman	NNP	_	51	nn	_
50	Leif	leif	NNP	_	51	nn	_
51	Johansson	johansson	NNP	_	52	nsubj	52:A0
52	said	say	VBD	pb=say.01	0	root	_
53	in	in	IN	_	52	prep	52:AM-LOC
54	a	a	DT	_	55	det	_
55	statement	statement	NN	_	53	pobj	_
56	.	.	.	_	52	punct	_

1	Pfizer	pfizer	NNP	p2=NN	3	poss	_
2	's	's	POS	_	1	possessive	_
3	approach	approach	NN	_	9	nsubj	9:A1=PPT;14:A1=PPT
4	throughout	throughout	IN	_	3	prep	_
5	its	its	PRP$	_	6	poss	_
6	pursuit	pursuit	NN	_	4	pobj	_
7	of	of	IN	_	6	prep	_
8	AstraZeneca	astrazeneca	NNP	_	7	pobj	_
9	appears	appear	VBZ	pb=appear.02	31	ccomp	31:A1=PPT
10	to	to	TO	_	14	aux	_
11	have	have	VB	_	14	aux	_
12	been	be	VBN	_	14	auxpass	_
13	fundamentally	fundamentally	RB	_	14	advmod	14:AM-MNR
14	driven	drive	VBN	pb=drive.02	9	xcomp	9:C-A1
15	by	by	IN	_	14	agent	14:A0=PAG
16	the	the	DT	_	19	det	_
17	corporate	corporate	JJ	_	19	amod	_
18	financial	financial	JJ	_	19	amod	_
19	benefits	benefit	NNS	_	15	pobj	_
20	to	to	IN	_	19	prep	_
21	its	its	PRP$	_	22	poss	_
22	shareholders	shareholder	NNS	_	20	pobj	_
23	of	of	IN	_	22	prep	_
24	cost	cost	NN	p2=JJ	25	nn	_
25	savings	saving	NNS	_	23	pobj	_
26	and	and	CC	_	25	cc	_
27	tax	tax	NN	_	28	nn	_
28	minimisation	minimisation	NN	_	25	conj	_
29	,	,	,	_	31	punct	_
30	he	he	PRP	_	31	nsubj	31:A0=PAG
31	added	add	VBD	pb=add.01	0	root	_
32	.	.	.	_	31	punct	_

1	"	"	``	p2=''	39	punct	_
2	From	from	IN	_	39	prep	_
3	our	our	PRP$	_	5	poss	_
4	first	#ord#	JJ	_	5	amod	_
5	meeting	meeting	NN	_	2	pobj	_
6	in	in	IN	_	5	prep	_
7	January	january	NNP	_	6	pobj	_
8	to	to	IN	_	2	prep	_
9	our	our	PRP$	_	11	poss	_
10	latest	late	JJS	_	11	amod	_
11	discussion	discussion	NN	_	8	pobj	_
12	yesterday	yesterday	NN	_	2	npadvmod	_
13	,	,	,	_	2	punct	_
14	and	and	CC	_	2	cc	_
15	in	in	IN	_	25	prep	25:AM-LOC
16	the	the	DT	_	19	det	_
17	numerous	numerous	JJ	_	19	amod	_
18	phone	phone	NN	_	19	nn	_
19	calls	call	NNS	p2=VBZ	15	pobj	_
20	in	in	IN	p2=RP	19	prep	_
21	between	between	IN	p2=NN	2	conj	_
22	,	,	,	_	25	punct	_
23	Pfizer	pfizer	NNP	_	25	nsubj	27:A0=PAG;25:A1=PAG
24	has	have	VBZ	_	25	aux	_
25	failed	fail	VBN	pb=fail.01	39	ccomp	39:A1=PPT
26	to	to	TO	_	27	aux	_
27	make	make	VB	pb=make.02	25	xcomp	25:A2=PPT
28	a	a	DT	_	35	det	_
29	compelling	compelling	JJ	_	35	amod	_
30	strategic	strategic	JJ	_	35	amod	_
31	,	,	,	_	30	punct	_
32	business	business	NN	_	35	nn	_
33	or	or	CC	_	32	cc	_
34	value	value	NN	_	32	conj	_
35	case	case	NN	_	27	dobj	27:A1=PRD
36	,	,	,	_	39	punct	_
37	"	"	''	p2=``	39	punct	_
38	Johansson	johansson	NNP	_	39	nsubj	39:A0
39	said	say	VBD	pb=say.01	0	root	_
40	.	.	.	_	39	punct	_

1	He	he	PRP	_	2	nsubj	2:A0=PAG
2	added	add	VBD	pb=add.01	0	root	_
3	that	that	IN	_	21	complm	_
4	"	"	``	_	21	punct	_
5	the	the	DT	_	6	det	_
6	price	price	NN	_	21	nsubj	23:A1=PPT;14:AM-LOC
7	at	at	IN	_	14	prep	14:R-AM-LOC
8	which	which	WDT	_	7	pobj	_
9	the	the	DT	_	10	det	_
10	Board	board	NNP	_	14	nsubj	17:A0=PAG;14:A1=PPT
11	of	of	IN	_	10	prep	_
12	AstraZeneca	astrazeneca	NNP	_	11	pobj	_
13	would	would	MD	_	14	aux	14:AM-MOD
14	be	be	VB	pb=be.01	6	rcmod	_
15	prepared	prepared	JJ	p2=VBN	14	acomp	14:A2=PRD
16	to	to	TO	_	17	aux	_
17	provide	provide	VB	pb=provide.01	15	xcomp	_
18	a	a	DT	_	19	det	_
19	recommendation	recommendation	NN	_	17	dobj	17:A1=PPT
20	would	would	MD	_	21	aux	21:AM-MOD
21	have	have	VB	pb=have.02	2	ccomp	2:A1=PPT
22	to	to	TO	_	23	aux	_
23	be	be	VB	pb=be.01	21	xcomp	_
24	more	more	JJR	_	26	amod	_
25	than	than	IN	_	26	quantmod	_
26	10	0	CD	_	28	num	_
27	per	per	NN	p2=IN	28	nn	_
28	cent	cent	NN	_	29	npadvmod	_
29	above	above	IN	_	23	prep	23:A2=PRD
30	the	the	DT	_	31	det	_
31	level	level	NN	_	29	pobj	32:A1
32	contained	contain	VBN	p2=VBD|pb=contain.01	31	partmod	_
33	in	in	IN	_	32	prep	32:A0
34	Pfizer	pfizer	NNP	_	37	poss	_
35	's	's	POS	_	34	possessive	_
36	Friday	friday	NNP	_	37	nn	_
37	proposal	proposal	NN	_	33	pobj	_
38	"	"	''	_	21	punct	_
39	.	.	.	_	2	punct	_

1	On	on	IN	_	5	prep	5:AM-TMP
2	Sunday	sunday	NNP	_	3	nn	_
3	Pfizer	pfizer	NNP	_	1	pobj	_
4	had	have	VBD	_	5	aux	_
5	issued	issue	VBN	pb=issue.01	0	root	_
6	a	a	DT	_	7	det	_
7	statement	statement	NN	_	5	dobj	8:A0=PAG;5:A1=PPT
8	making	make	VBG	pb=make.01	7	partmod	_
9	a	a	DT	_	11	det	_
10	final	final	JJ	_	11	amod	_
11	proposal	proposal	NN	_	8	dobj	8:A1=PRD;17:AM-LOC
12	under	under	IN	_	17	prep	17:R-AM-LOC
13	which	which	WDT	_	12	pobj	_
14	AstraZeneca	astrazeneca	NNP	_	15	nn	_
15	shareholders	shareholder	NNS	_	17	nsubj	17:A0=PAG
16	would	would	MD	_	17	aux	17:AM-MOD
17	receive	receive	VB	pb=receive.01	11	rcmod	_
18	,	,	,	_	17	punct	_
19	for	for	IN	_	17	prep	_
20	each	each	DT	_	22	det	_
21	AstraZeneca	astrazeneca	NNP	_	22	nn	_
22	share	share	NN	p2=VBP	19	pobj	_
23	,	,	,	_	17	punct	_
24	1.747	0	CD	_	25	num	_
25	shares	share	NNS	_	17	dobj	17:A1=PPT
26	in	in	IN	_	17	prep	_
27	the	the	DT	_	29	det	_
28	combined	combined	JJ	p2=VBN	29	amod	_
29	entity	entity	NN	_	26	pobj	_
30	and	and	CC	_	17	cc	_
31	2,476	0	CD	_	32	num	_
32	pence	penny	NNS	p2=NN	17	conj	_
33	in	in	IN	_	32	prep	_
34	cash	cash	NN	_	33	pobj	_
35	,	,	,	_	32	punct	_
36	representing	represent	VBG	pb=represent.01	32	partmod	_
37	an	an	DT	_	39	det	_
38	indicative	indicative	JJ	_	39	amod	_
39	value	value	NN	_	36	dobj	36:A1=PPT
40	of	of	IN	_	39	prep	_
41	£55.00	£0	NN	p2=CD	40	pobj	_
42	(	(	-LRB-	_	41	punct	_
43	$	$	$	_	44	nmod	_
44	92.53	0	CD	_	41	appos	_
45	)	)	-RRB-	_	41	punct	_
46	per	per	IN	_	41	prep	_
47	share	share	NN	_	46	pobj	_
48	.	.	.	_	5	punct	_

1	The	the	DT	_	3	det	_
2	US	us	NNP	_	3	nn	_
3	firm	firm	NN	_	5	nsubj	5:A0=PAG
4	had	have	VBD	_	5	aux	_
5	urged	urge	VBN	pb=urge.01	0	root	_
6	"	"	``	p2=''	9	punct	_
7	supportive	supportive	JJ	_	9	amod	_
8	AstraZeneca	astrazeneca	NNP	p2=JJ	9	nn	_
9	shareholders	shareholder	NNS	_	5	dobj	11:A0=PAG;5:A1=PPT
10	to	to	TO	_	11	aux	_
11	urge	urge	VB	pb=urge.01	5	xcomp	5:A2=PPT
12	the	the	DT	_	14	det	_
13	AstraZeneca	astrazeneca	NNP	_	14	nn	_
14	board	board	NN	_	11	dobj	16:A0=PAG;22:A0=PAG;11:A1=PPT
15	to	to	TO	_	16	aux	_
16	begin	begin	VB	pb=begin.01	11	xcomp	11:A2=PPT
17	substantive	substantive	JJ	_	18	amod	_
18	engagement	engagement	NN	_	16	dobj	16:A1=PPT
19	with	with	IN	_	18	prep	_
20	Pfizer	pfizer	NNP	p2=NN	19	pobj	_
21	and	and	CC	_	16	cc	_
22	extend	extend	VB	pb=extend.01	16	conj	_
23	the	the	DT	_	24	det	_
24	period	period	NN	_	22	dobj	22:A1=PPT
25	for	for	IN	_	24	prep	_
26	such	such	JJ	_	27	amod	_
27	talks	talk	NNS	_	25	pobj	_
28	prior	prior	RB	p2=JJ	22	advmod	_
29	to	to	IN	_	28	prep	_
30	the	the	DT	_	33	det	_
31	May	may	NNP	_	33	nn	_
32	26	0	CD	_	31	num	_
33	deadline	deadline	NN	_	29	pobj	_
34	for	for	IN	_	33	prep	_
35	making	make	VBG	pb=make.LV	34	pcomp	_
36	an	an	DT	_	37	det	_
37	offer	offer	NN	_	35	dobj	35:AM-PRR
38	"	"	''	_	5	punct	_
39	.	.	.	_	5	punct	_

